ArticleJournal of virology2025
Local and introduced lineages drive MERS-CoV recombination in Egyptian camels.
Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Dromedary camels are the primary reservoir for Middle East respiratory syndrome coronavirus (MERS-CoV), a zoonotic coronavirus responsible for sporadic human infections. While clade B predominates in the Arabian Peninsula and is frequently linked to zoonotic outbreaks and household secondary transmission, clade C circulates primarily in African camels, with limited evidence of human infections. The extent of MERS-CoV transmission, genetic diversity, and cross-species potential in North Africa remains poorly characterized. Here, we investigate MERS-CoV incidence, seroprevalence, and genomic recombination in dromedary camels and sympatric livestock across slaughterhouses and farms in Egypt. MERS-CoV was detected in 12% of camels sampled at slaughterhouses, with no evidence of infection in cattle, buffalo, sheep, or goats. Seroprevalence was higher in slaughtered camels (79%) than camels on farms (12%). Phylogenetic analyses of MERS-CoV genomes obtained from dromedary camels revealed an introduction of clade B into Egypt, originating from the Arabian Peninsula. Furthermore, we identified recombination events between clades B and C, in addition to events within each clade. This included at least one clade C virus that acquired multiple genomic regions from the newly introduced clade B viruses. These findings suggest that newly introduced MERS-CoV strains can recombine with locally circulating viruses, generating novel variants with potential zoonotic implications and challenging assumptions of limited cross-regional exchange. Enhanced surveillance, targeted control measures, and a One Health approach are crucial to mitigating MERS-CoV transmission and the emergence of recombinant strains. IMPORTANCE: This study highlights the importance of monitoring Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels, which are the main animal source of this virus that can occasionally infect humans. While most human cases have been linked to strains in the Arabian Peninsula, this research focused on Egypt, where the virus is less understood. Among surveyed dromedary camels and associated livestock, a significant number of camels at slaughterhouses were infected, and many had antibodies showing past exposure. Importantly, we discovered that a strain common in the Arabian Peninsula had recently entered Egypt and mixed genetically with local strains. This mixing, or recombination, can lead to new virus versions that may pose new risks to humans. The findings challenge the belief that MERS-CoV strains in different regions do not interact and highlight the need for stronger monitoring and prevention strategies. A One Health approach, linking animal, human, and environmental health, is key to managing future risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.